loading
Schlusskurs vom Vortag:
$1.51
Offen:
$1.5
24-Stunden-Volumen:
545.61K
Relative Volume:
0.37
Marktkapitalisierung:
$97.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.315
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
+10.85%
1M Leistung:
-23.53%
6M Leistung:
-49.47%
1J Leistung:
-86.98%
1-Tages-Spanne:
Value
$1.41
$1.505
1-Wochen-Bereich:
Value
$1.275
$1.565
52-Wochen-Spanne:
Value
$1.01
$13.24

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name
Firmenname
Zentalis Pharmaceuticals Inc
Name
Telefon
(858) 263-4333
Name
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Name
Mitarbeiter
166
Name
Twitter
@ZentalisP
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
ZNTL's Discussions on Twitter

Vergleichen Sie ZNTL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ZNTL
Zentalis Pharmaceuticals Inc
1.43 97.66M 0 -292.19M -208.41M -4.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-12 Hochstufung Wedbush Underperform → Neutral
2024-06-20 Herabstufung UBS Buy → Neutral
2024-06-18 Herabstufung Jefferies Buy → Hold
2024-06-18 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-06-18 Herabstufung Wedbush Neutral → Underperform
2024-06-18 Herabstufung Wells Fargo Overweight → Equal Weight
2023-11-08 Herabstufung Wedbush Outperform → Neutral
2023-11-07 Herabstufung Leerink Partners Outperform → Market Perform
2022-07-12 Eingeleitet Cowen Outperform
2022-04-06 Eingeleitet Wells Fargo Overweight
2021-10-07 Fortgesetzt Jefferies Buy
2021-09-30 Eingeleitet Stifel Buy
2021-09-29 Eingeleitet Oppenheimer Outperform
2021-05-21 Eingeleitet UBS Buy
2021-01-20 Eingeleitet Wedbush Outperform
2020-09-29 Eingeleitet Cantor Fitzgerald Overweight
2020-08-27 Eingeleitet H.C. Wainwright Buy
2020-04-28 Eingeleitet Guggenheim Buy
2020-04-28 Eingeleitet Jefferies Buy
2020-04-28 Eingeleitet Morgan Stanley Overweight
2020-04-28 Eingeleitet SVB Leerink Outperform
Alle ansehen

Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten

pulisher
03:55 AM

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Increased by Russell Investments Group Ltd. - Defense World

03:55 AM
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

Zentalis Pharmaceuticals Inc (ZNTL) deserves deeper analysis - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Chief Medical Officer Bruns Ingmar acquire 20,000 shares of Zentalis Pharmaceuticals Inc [ZNTL] - knoxdaily.com

Apr 24, 2025
pulisher
Apr 23, 2025

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Zentalis Pharmaceuticals Announces Poster Presentation at ASCO 2025 on Azenosertib for Colorectal Cancer - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

New Clinical Data: Zentalis's Novel Cancer Drug Shows Promise in Metastatic Colorectal Cancer Treatment - Stock Titan

Apr 23, 2025
pulisher
Apr 23, 2025

JPMorgan Chase & Co. Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 23, 2025
pulisher
Apr 19, 2025

Franklin Resources Inc. Buys Shares of 106,748 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 19, 2025
pulisher
Apr 14, 2025

Raymond James Financial Inc. Takes Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 14, 2025
pulisher
Apr 12, 2025

12,840 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Acquired by Prudential Financial Inc. - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

Sei Investments Co. Purchases Shares of 35,320 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 12, 2025
pulisher
Apr 10, 2025

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL): Can The Stock Still Lose Despite An -61.39% YTD Loss? - Marketing Sentinel

Apr 10, 2025
pulisher
Apr 08, 2025

Zentalis stock plunges to 52-week low at $1.08 amid market challenges - Investing.com Canada

Apr 08, 2025
pulisher
Apr 08, 2025

Lost Money on Zentalis Pharmaceuticals, Inc.(ZNTL)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 08, 2025

ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 05, 2025

Thrivent Financial for Lutherans Grows Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 05, 2025
pulisher
Apr 03, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 01, 2025
pulisher
Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Zentalis Strengthens Team with $194,600 in Equity Incentives - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

Virtu Financial LLC Buys Shares of 24,973 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

Leerink Partnrs Issues Pessimistic Outlook for ZNTL Earnings - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Forecast for ZNTL Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

Leerink Partnrs Has Pessimistic Outlook of ZNTL Q1 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Lifted by Charles Schwab Investment Management Inc. - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Wedbush Reiterates Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Bank of New York Mellon Corp Sells 10,375 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Zentalis Pharmaceuticals Reports Progress and Financials - TipRanks

Mar 28, 2025
pulisher
Mar 27, 2025

Stifel maintains Buy on Zentalis stock with $9 target By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

H.C. Wainwright sets $10 target for Zentalis shares, maintains Buy By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates - The Manila Times

Mar 27, 2025
pulisher
Mar 26, 2025

Zentalis Pharmaceuticals Inc Reports Annual EPS of -$2.33, Excee - GuruFocus

Mar 26, 2025
pulisher
Mar 26, 2025

Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Zentalis Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Zentalis Breakthrough: 35% Response Rate in Ovarian Cancer Trial Wins FDA Fast Track - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Zentalis Pharmaceuticals to Present Multiple Posters at the - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Major Cancer Breakthrough: Zentalis Reveals New Azenosertib Data Across Multiple Tumor Types - Stock Titan

Mar 25, 2025
pulisher
Mar 21, 2025

Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 20, 2025

Zentalis pharmaceuticals director Luke Walker buys $24,966 in stock - MSN

Mar 20, 2025
pulisher
Mar 19, 2025

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright - The AM Reporter

Mar 19, 2025
pulisher
Mar 17, 2025

H.C. Wainwright maintains $10 target on Zentalis stock By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Zentalis Highlights Promising Azenosertib Data at SGO 2025 - TipRanks

Mar 17, 2025
pulisher
Mar 15, 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at - GlobeNewswire

Mar 15, 2025
pulisher
Mar 15, 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - MarketScreener

Mar 15, 2025
pulisher
Mar 15, 2025

Zentalis Announces Updated Clinical Data From Part 1b Of DENALI Trial Of Azenosertib In PROC - Nasdaq

Mar 15, 2025
pulisher
Mar 15, 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - TradingView

Mar 15, 2025
pulisher
Mar 11, 2025

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Has Been Trading Down. What Are The Prospects For The Future? - stocksregister.com

Mar 11, 2025

Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):